Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data

SUMMARY: This study showed that risedronate 150-mg once a month provides similar efficacy and safety at 2 years compared with risedronate 5-mg daily for the treatment of postmenopausal osteoporosis. This adds to the range of risedronate dosing options and provides an alternative for patients who pre...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: McClung, M. R., Zanchetta, J. R., Racewicz, A., Roux, C., Benhamou, C.-L., Man, Z., Eusebio, R. A., Beary, J. F., Burgio, D. E., Matzkin, E., Boonen, S., Delmas, P.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer-Verlag 2012
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3536944/
https://ncbi.nlm.nih.gov/pubmed/22752050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00198-012-2056-0
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia